ClinicalTrials.Veeva

Menu

Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer (FOGT1)

U

University of Ulm

Status and phase

Completed
Phase 3

Conditions

Rectal Cancer

Treatments

Drug: Folinic Acid, interferon-alpha

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The primary objective was to improve adjuvant 5-FU chemoradiotherapy in resectable rectal cancer. The investigators hypothesis was that modulation of 5-FU by addition of either FA or INF-alpha may increase overall survival.

Full description

Primary endpoint was overall survival (OS). For sample size estimation the following assumptions were made: The 5-year OS rate of 5-FU was estimated to be 58%. Our intention was to detect an increase in the 5-year OS rate by one of the additives of at least 10% with a power of 80% and a level of significance of 5% in comparison to 5-FU (one-sided). Hypotheses were analyzed as pair wise comparisons between the treatment options. This resulted in a target sample size of 280 patients per group and a total of 840 patients.

Enrollment

796 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Eligibility was defined as potentially curative en-bloc resection (R0) of an adenocarcinoma of the rectum with a lower tumor edge within 12 cm from the anal verge determined by rectoscopy, a pathologic UICC stage II (pT3/4pN0M0) or III (pT1-4pNposM0) with examination of at least 12 lymph nodes, a white blood count ≥ 3,500/µl, a platelet count ≥ 100,000/µl, a ECOG performance status of 0 or 1, and written informed consent.

Exclusion criteria

  • Ineligible were patients not fulfilling these criteria or having a history of cancer except for adequately treated superficial basal or squamous cell skin cancer or in situ carcinoma of the cervix, getting previous radio- or chemotherapy, pregnant or nursing women, other having severe concomitant diseases limiting life expectancy or not allowing chemotherapy, and with social conditions not allowing a 5-year follow-up.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

796 participants in 3 patient groups

5-FU
Active Comparator group
Description:
Standard arm Systemic drug administration of 5-FU (intravenous)
Treatment:
Drug: Folinic Acid, interferon-alpha
5-FU + folinic acid
Experimental group
Description:
Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
Treatment:
Drug: Folinic Acid, interferon-alpha
5-FU + Interferon-alpha
Experimental group
Description:
Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
Treatment:
Drug: Folinic Acid, interferon-alpha

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems